



December 6, 2024

To Whom It May Concern

Company: KYORIN Pharmaceutical Co., Ltd.  
Representative: Yutaka Ogihara  
Representative Director, President and CEO  
(Security Code: 4569, TSE Prime.)  
Contact: Yoshinori Tanifuji  
Director, Corporate Planning  
Telephone: 03-6374-9702

## Notice of the Relocation of the Nishinohon Distribution Center

KYORIN Pharmaceutical Co., Ltd. announced that effective January 6, 2025, our Nishinohon Distribution Center will be relocated from Kumiyaama office, LOGISTEED West Japan, Ltd. (Kuse-gun, Kyoto) to Kansai III Medical Distribution Center LOGISTEED West Japan, Ltd. (Sanda-shi, Hyogo)

KYORIN closed previous Nishinohon Distribution Center due to a fire occurred in November 2021, and established its current distribution center in June 2022. In order to further strengthen its GDP\*1 Management System and BCP\*2, this time KYORIN has decided to relocated the Nishinohon Distribution Center.

Together with Higashinohon Distribution Center, we will continue to operate a two-site logistics system in the east and west regions, striving to strengthen our supply chain and ensure stable supply.

The impact of this matter on the financial forecast for the fiscal year ending March 2025 has already reflected.

\*1 GDP : Good Distribution Practice

\*2 BCP : Business Continuity Planning

Name	KYORIN Pharmaceutical Co., Ltd. Nishinohon Distribution Center
Location	39 Techno Park, Sanda-shi, Hyogo c/o Kansai III Medical Distribution Center, LOGISTEED West Japan, Ltd.
Date	January 6, 2025

